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Recently, we reported that 1,2-dipalmitoyl-sn-glycero-3-phosphoglyceroglycerol (DPPGOG) prolongs the circulation time of thermosensitive
liposomes (TSL). Since the only TSL formulation in clinical trials applies DSPE-PEG2000 and lysophosphatidylcholine (P-lyso-PC), the
objective of this study was to compare the influence of these lipids with DPPGOG on in vitro stability and heat-induced drug release properties of
TSL. The content release rate was significantly increased by incorporating DPPGOG or P-lyso-PC in TSL formulations. DPPC/DSPC/DPPGOG
50:20:30 (m/m) and DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m) did not differ significantly in their release rate of carboxyfluorescein with
N70% being released within the first 10s at their phase transition temperature. Furthermore, DPPC/DSPC/DPPGOG showed an improved stability
at 37 °C in serum compared to the PEGylated TSL. The in vitro properties of DPPGOG-containing TSL remained unchanged when encapsulating
doxorubicin instead of carboxyfluorescein. The TSL retained 89.1±4.0% of doxorubicin over 3 h at 37 °C in the presence of serum. The drug was
almost completely released within 120s at 42 °C. In conclusion, DPPGOG improves the in vitro properties in TSL formulations compared to
DSPE-PEG2000, since it not only increases the in vivo half-life, it even increases the content release rate without negative effect on TSL stability
at 37 °C which has been seen for DSPE-PEG2000/P-lyso-PC containing TSL.
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Liposomes are composed of lipid bilayers entrapping an
internal aqueous space [1]. To avoid rapid opsonization and
subsequent uptake of liposomes by the reticuloendothelial
system (RES), the surface of liposomes is often modified with
Poly(ethylene glycol) (PEG), e.g. by using 1,2-distearoyl-sn-
glycero- 3-phosphoethanolamine-N-[methoxy(polyethylene
glycol)-2000] (DSPE-PEG2000) (Fig. 1). This PEGylation
strongly increases the circulation half-life of cholesterol-⁎ Corresponding author. Ludwig-Maximilians Universität, Medizinische
Klinik III, Klinikum Grosshadern, Marchioninistr. 15, D-81377 Munich,
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doi:10.1016/j.bbamem.2007.05.021containing [2–4] and cholesterol-free liposomes [5] after
intravenous application. The escape mechanism of liposomes
from the RES remains enigmatic [5].
Side effects of cytotoxic drugs like doxorubicin (DOX) or
amphotericin B (Ambisome®) are significantly reduced by
liposomal encapsulation. This has been demonstrated in various
clinical studies using PEGylated-liposomal DOX (Caelyx®,
Doxil®) and non-PEGylated DOX (Myocet™) with regard to
cardiotoxicity [6,7]. Ambisome® shows less infusion-related
toxicity and less nephrotoxicity in comparison to conventional
amphotericin B [8]. However, compared to free drug, no
improved effectiveness of these clinically approved liposomal
formulations has been reported [8,9].
In 1978 Yatvin and colleagues introduced liposomes that
release neomycin at specific temperatures and inhibit bacteria
Fig. 1. Chemical structure of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[Methoxy(Polyethylene glycol)-2000] (DSPE-PEG2000) and 1,2-dipalmitoyl-sn-
glycero-3-phosphoglyceroglycerol (DPPGOG).
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liposomes (TSL) were further developed over the last decades
[11–15]. Generally, at their phase transition temperature (Tm)
lipids change from the “solid” gel to the “fluid” liquid
crystalline state [16]. A conformational change of C–C single
bonds in the alkyl chains of the lipids leads to an increase in the
total volume occupied by the hydrocarbon chains in the
membrane, and therefore increases the permeability of the
bilayer membrane. At Tm the permeability is additionally
increased as a result of the coexistence of membrane areas in
both phases [17]. Moreover, with the incorporation of lysopho-
sphatidylcholines (e.g. 1-palmitoyl-2-hydroxy-sn-glycero-3-
phosphocholine, P-lyso-PC) into the liposomal membrane it is
possible to further accelerate the content release rate at Tm
[18,19]. Since P-lyso-PC has a conical molecular shape with the
tendency to form spherical micelles in solution, the formation of
membrane pores is discussed as a mechanism for increased
permeability [15]. The combination of miscible lipids with
different Tm results in membranes with a Tm in between those of
each lipid [16]. The original formulation based on DPPC
(Tm=4 °C [20]) and DSPC (Tm=54.9 °C [20]) with a 3:1 molar
ratio released its content between 42.5 and 44.5 °C [10].
Hauck and colleagues reported recently the first phase I trial
with TSL in dogs [21]. They treated spontaneous canine
tumours with DOX encapsulated in DPPC/P-lyso-PC/DSPE-
PEG2000 90:10:4 (m/m) and local hyperthermia. Remarkably,
the maximum tolerable dose was slightly lower than known for
free DOX or Caelyx®/Doxil® in dogs and the pharmacokinetic
profile was also more comparable to free than to liposomally
encapsulated drug. The authors attributed this to the fact that
DOX was released so rapidly in the heated tumour. However,
the average area under the curve as well as the intratumoural
drug levels were significantly higher when compared to free
DOX.
Recently, we reported a novel formulation of TSL with a
prolonged half-life in vivo without the use of PEGylated lipids
[14]. This was achieved by the synthetic lipid dipalmitoyl-sn-
glycero-3-phospho-glyceroglycerol (DPPGOG) in the formula-
tion DPPC/DSPC/DPPGOG 50:20:30 (m/m). The structure of
DPPGOG is based on the natural lipid 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol and contains an additional glycerol
molecule bound to the glycerol head group via an ether bond
(Fig. 1).
The objective of this study was to compare the influence of
DPPGOG, DSPE-PEG2000 and/or P-lyso-PC on the in vitro
stability and drug release properties of TSL formulations. The
DPPGOG-containing formulation DPPC/DSPC/DPPGOG
50:20:30 (m/m) was compared to DPPC/P-lyso-PC/DSPE-
PEG2000 90:10:4 (m/m) and PEGylated TSL without P-lyso-
PC in presence of fetal calf serum (FCS) to simulate in vivo
conditions. The amount of encapsulated carboxyfluorescein
(CF) was used to reveal the influence of the different lipids on
the TSL properties. Encapsulation of CF is a high-precise
method that allows the artefact-free detection of even low
marker concentrations in serum. Whereas the fluorescence of
the encapsulated CF dye is low due to self-quenching at a
concentration of 100 mM, an intense signal appears after CF-
release from TSL as a result of liberation and dilution in the
outer medium [22]. Furthermore, DOX was encapsulated in
DPPC/DSPC/DPPGOG 50:20:30 (m/m) to obtain a therapeu-
tically relevant formulation. The release and stability properties
of this formulation were compared to the CF containing
formulation.
2. Materials and methods
2.1. Chemicals
The phospholipids DPPC, DSPC and P-lyso-PC were purchased from
Genzyme Pharmaceuticals (Sygena Ltd., Liestal, Switzerland). DSPE-PEG2000
was obtained from Avanti Polar Lipids (Alabaster, Alabama, USA). The lipid
DPPGOG was synthesized (PCT/WO97/30058) as described previously [23].
Carboxyfluorescein (CF) was purchased from Fluka (Buchs, Switzerland) and
additionally purified by recrystallization. Doxorubicin was obtained from Sigma
Aldrich (München, Germany) and Caelyx® from Essex Pharma GmbH
(München, Germany). For high-performance thin layer chromatography
(HPTLC) 0.22 mm thick, chemically unmodified silica gel 60 coated on glass
plates (Macherey-Nagel, Düren, Germany) was used.
2.2. Preparation of TSL with encapsulated CF
Liposomes were prepared by the lipid film hydration and extrusion
method [24]. The composition of the different formulations used in this study
are given in Table 1. Respective lipids were dissolved in chloroform using a
round-bottomed flask, and the solvent was evaporated under vacuum in a
rotary evaporator until a thin and homogeneous lipid film was formed.
Hydration of the film was performed using 100 mM CF solution, pH 7.2 at
60 °C for 30 min. The resulting lipid concentration was 50 mM. Unilamellar
vesicles were obtained by seventeen times extrusion through two poly-
carbonate nanopore filters of 200 nm pore size (Avestin, Canada) using a
thermobarrel extruder at 60 °C (custom-made; MPI for Biophysical
Chemistry, Goettingen, Germany). Unencapsulated CF was removed from
the liposome suspension by gel filtration through a Sephadex G-50 column
(Pfizer, New York, NY), eluting in 0.9% NaCl solution.
2.3. Preparation of TSL with encapsulated DOX
For the encapsulation of DOX a pH-gradient-driven loading method was
carried out [25], with minor modifications. In brief, the TSL were prepared as
described above but 300 mM citrate, pH 4 was used for the hydration process
instead of CF. Unencapsulated citrate was removed from the liposome
suspension by gel filtration through a Sephadex G-50 column equilibrated
with 20 mM HEPES, 150 mM NaCl, pH 7.4 (HN buffer). TSL and DOX were
Table 1
Characterization of the CF-TSL (n represents the number of independent preparations)
Liposome c (lipid)
(mM)
ζ-potential
(mV)
Size
(z average) (nm)
Tm
(°C)
Polydispersity
index
CF:lipid
(m:m)
head group
modified lipid (%)
CF-leakage
1 h/37 °C in FCS (%)
DPPC/DSPC/DPPGOG 50:20:30 (m/m)
(n=7) 41.5 (±9.6) −22.5 (±9.2) 168 (±8) 42.4 (±0.1) 0.05 (±0.02) 0.19 (±0.03) 27.2 (±3.3) 3.9 (±1.1)
DPPC/DSPC/DSPE-PEG2000 80:20-x:x (m/m)
x=0 (n=3) 37.8 (±11.1) 0.1 (±0.3) 170 (±12) 43.1 (±1.5) 0.06 (±0.04) 0.17 (±0.03) – 2.1 (±1.1)
x= 1 (n=2) 40.0 (±5.4) 1.3 (±1.1) 153 (±47) 43.6 (±0.3) 0.31 (±0.12) 0.21 (±0.08) 1.0 (±0.0) 1.7 (±0.8)
x= 5 (n=3) 35.9 (±7.1) 1.2 (±1.7) 141 (±37) 43.7 (±0.2) 0.10 (±0.05) 0.21 (±0.05) 4.4 (±0.4) 2.4 (±2.2)
x=10 (n=2) 40.8 (±1.8) −2.7 (±0.9) 144 (±11) 43.5 (±0.2) 0.09 (±0.01) 0.12 (±0.02) 10.6 (±1.6) 3.6 (±4.2)
DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m)
(n=3) 47.3 (±5.3) −2.0 (±2.0) 141 (±3) 40.9 (±0.1) 0.05 (±0.02) 0.20 (±0.02) 3.3 (±0.2) 2.9 (±0.6)
The standard deviations are given in parenthesis.
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incubated at 38 °C for DOX loading.
2.4. Thin layer chromatography
The phospholipid composition of liposomes was analyzed by thin layer
chromatography. Therefore 1 μmol TSL was diluted with water to obtain a total
volume of 0.5 mL. Subsequently, 0.5 mL 20% NaCl and 2 mL chloroform:
methanol 1:1 (v/v) were added. The solution was mixed and centrifuged to
separate the phases. The organic phase was removed and collected. The aqueous
phase was reextracted with chloroform:methanol 3:1 (v/v). The combined
chloroform extracts were freed from solvent at 40 °C under a steady stream of
nitrogen. For TLC analysis 20 mM solutions of lipids were prepared in
chloroform:methanol 9:1 (v/v). After application of the samples on silica gel 60
HPTLC plates, the lipids were developed with chloroform:methanol:ammonia
(5%) 60:40:1 (v/v) as solution. The poor separation of DPPC and DSPC did not
allow the calculation of the DPPC:DSPC ratio. For DSPE-PEG2000 chloro-
form:methanol 9:1 (v/v) was used as a solution system, where DSPE-PEG2000
formed well-defined spots. Selective staining of phospholipids was performed
using the phosphate molybdenum spray of Dittmer and Lester [26].
2.5. Differential scanning calorimetry
Differential scanning calorimetry (DSC) was used to study the phase
transition temperature of the unilamellar vesicles with different lipid composi-
tions. The liposome suspensions were transferred into 40 μL aluminium
crucibles without pin (ME 26763) sealed and analyzed using a Mettler Toledo
DSC 822e (Giessen, Germany). The samples were scanned from 20 to 60 °C at
an average heating rate of 1 °C/min.
2.6. Photon correlation spectroscopy
The size and ζ-potential of the resultant unilamellar vesicles were determined
by photon correlation spectroscopy (PCS) in a Zetasizer 3000 (Malvern
Instruments, Worcestershire, United Kingdom). For the size measurements the
TSL were diluted in water, while the ζ-potential was obtained in 0.9% NaCl.
2.7. Determination of TSL concentration
The overall concentration of phospholipids in the TSL was determined by
phosphate analysis as described previously [27].
2.8. Determination of the doxorubicin concentration
The concentration of DOX in the TSL preparations was measured using a
Waters HPLC system, with 510 HPLC pumps, 717plus autosampler and the 470
fluorescence detector with an excitation wavelength of 480 nm and an emission
wavelength of 560 nm. As described previously [28], the measurement wasperformed with minor modifications. The runs were carried out on a C18 column
(250 mm×4.6 mm internal diameter, 5 μm particle size; 125 Å pore size) from
Phenomenex Ltd., Germany. The samples were prepared by an extraction
protocol as follows: TSL were diluted to 1 mL using phosphate buffered saline.
To each sample, 100 μL internal standard (daunorubicin, 10 μg/mL) and 10 mL
dichlormethane/isopropanole 9:1 (v/v) was added. After vigorous mixing, the
sample was centrifuged and the obtained organic phase was transferred to a fresh
tube. Under a steady stream of nitrogen at 40 °C the extract was freed from
solvent. The sediment was dissolved in 1 mL 80 mM potassium dihydrogenpho-
sphate/acetonitrile 73:27 (v/v), also serving as eluent. After centrifugation, the
solvent was transferred to injection tubes. 50 μL per sample was injected and
eluted with a flow of 1 mL/min. A commercially available 2 mg/mL doxorubicin
solution for injection in humans (Adriblastin, Pfizer AG, Germany) was used as
standard.
2.9. Temperature dependent CF release
For quantification of entrapped CF, an aliquot of 20 μL liposome suspension
(1mM)was added to 200 μL of 2%Triton X-100 in water. After vigorousmixing
and heating at 45 °C for 15 min, 20 μL of this solution was adjusted to a total
volume of 1 mL with Tris/NaCl 0.9% buffer [10 mM (pH 8.0)] and the
fluorescence (Ex. 493 nm/Em. 513 nm) was measured in a spectrofluorometer
(RF-540 from Shimadzu, Kyoto, Japan). The obtained value was taken as 100%
release (I∞). Parallel to the incubation with detergent, 20 μL liposome suspension
was added to 200 μL of fetal calf serum (FCS, Invitrogen, Carlsbad, CA). Each
sample was kept in a thermoshaker (Eppendorf, Hamburg, Germany) and
incubated for the required time period at constant temperature (for detailed
parameters see Results). After incubation, 980 μLTris/NaCl 0.9% buffer [10 mM
(pH 8.0)] was added and the amount of free CF was determined as described
above. CF release was calculated as:
CF release ð%Þ ¼ ðIðtÞ  I0Þ=ðIl  I0ÞT100 ð1Þ
where I(t) is the fluorescence intensity after incubation of TSL for the time period
t and I0 is the fluorescence baseline.
2.10. Time dependent CF release
The time dependent CF-release of the different TSL formulations was
studied at their Tm to allow the comparison of the different formulations. Three
mL of FCS were incubated at the desired temperature in a Cary Eclipse
fluorescence spectrometer (Varian Inc., Palo Alto, CA, USA) using the
implemented heating device, until thermal equilibrium was reached. For the
final measurement, 10 μL liposome suspension was diluted with 490 μL 0.9%
NaCl. Twenty μL of this solution was given to the heated FCS under stirring and
the increase in fluorescence over time (I(t)) was measured at an excitation
wavelength of 493 nm and an emission wavelength of 513 nm. With the addition
of a small sample volume of TSL the formulations immediately reached their Tm
at time point t=0 s. For quantification of liposomal entrapped CF, 20 μL of 10%
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100% release (I∞). In the measured concentration range, the fluorescence of a CF
standard solution in FCS displayed a linear correlation with the concentration of
the dye (R=0.9992), indicating no interfering quenching effects. The CF release
was calculated using Eq. (1).
The leakage rate of liposomal content follows first order kinetics [29].
Komatsu and Okada used this assumption to calculate the rate constant k of CF-
leakage from liposomes treated with ethanol [30], with Eq.(2).
lnð1 IðtÞ=IlÞ ¼ A kt ð2Þ
A is expressed as ln(1− I0/I∞), with I0 as the initial fluorescence intensity. While
plotting ln(1− I(t)/I∞) against the incubation time t, k could be calculated using
linear regression. The first 20 s of incubation at Tm were used for calculation of k.
2.11. Time dependent DOX release
All DOX release measurements were carried out using a Varian Cary Eclipse
fluorescence spectrometer. It was possible to measure a single sample over the
whole time period as the implemented xenon flash lamp is only active when a
data point is acquired. Hence, constant excitation of DOX was avoided, so the
sample showed no photobleaching. Measurements were accomplished as
described above for the time dependent CF release with minor modifications.
Undiluted samples were added directly to the preheated FCS or HN buffer (37 to
45 °C, 1 °C steps) over a time period of up to 180 min. In the measured
concentration range, the fluorescence of a DOX standard solution in FCS or HN
buffer was linear with the concentration of the dye (RN0.99) indicating no
interfering quenching effects. The obtained equation from linear regression
could be used to quantify the DOX concentration in the samples. Percentage
DOX-release was calculated according to Eq. (1). For calculation of kDOX with
Eq. (2), the first 120 s of incubation at desired temperatures was used. It was
necessary to measure at high amplification, so the fluorescence of FCS had to
been taken into account. With the Varian Cary Eclipse fluorescence spectro-
meter, it was possible to measure up to 4 samples simultaneously. Therefore,
FCS reference samples were analyzed in all measurements with DOX containing
samples to obtain and subtract the FCS background fluorescence.
2.12. Statistical analysis
The data are expressed as the mean±standard deviation (S.D.) of triplicate
samples of at least three independent measurements.Fig. 2. Temperature dependent CF-release profile of different TSL.After diluting the
liposomes with FCS to an appropriate concentration the samples were incubated at
the desired temperature for 5min. TheCF releasewasmeasured from37 to 48 °C for
each formulation. Whereas the DPPC/DSPC/DSPE-PEG2000 and the DPPGOG-
containing TSL released CF around 42 °C, DPPC/P-lyso-PC/DSPE-PEG2000
90:10:4 (m/m) started the CF release between 39 and 40 °C. The formulations are
given as DPPC/DSPC/DPPGOG/DSPE-PEG2000/P-lyso-PC (m/m).3. Results
3.1. Preparation and characterization of TSL with
encapsulated CF
To compare the influence of DPPGOG and DSPE-PEG2000 on
the in vitro properties of DPPC/DSPC-based TSL, the formulations
DPPC/DSPC/DSPE-PEG2000 80:20-x:x (m/m) (x=1, 5, 10) and
DPPC/DSPC/DPPGOG 50:20:30 (m/m) were prepared besides
DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m). Thus, the ratio
of palmitic- and stearic acid esters in theTSLwaskept constantwith
80/20mol%and a direct comparison betweenDSPE-PEG2000 and
DPPGOG-containing formulations was made feasible.
The TSL with encapsulated CF (CF-TSL) were assayed and
their properties compared with the analytical protocol, based on
phospholipid concentration, size, ζ-potential, CF to lipid ratio
and Tm (Table 1). HPTLC was used to assay the phospholipid
composition quantitatively. The correlation between targeted
composition and real lipid ratio measured densitometrically is
given for all formulations (Table 1 and data not shown). No
signs of decomposition have been observed.Although DPPGOG and DSPE-PEG2000 are both negatively
charged lipids, only the CF-TSL composed of DPPGOG
exhibited a negative ζ-potential. CF-TSL with DSPE-PEG2000
showed a ζ-potential around zero, which could be explained by
the shielding effect of the PEG moiety [31]. The size of all TSL
varied between 141 and 170 nm. The obtained size of 141±3 nm
for the DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m) for-
mulation was consistent with the observation by Needham et al.
[19]. The observation that increasing DSPE-PEG2000 content
decreases the size of the TSL was not statistically significant. The
size distribution obtained was dependent on the formulation used.
Incorporation of 1 and 5 mol% DSPE-PEG2000 yielded a broad
size distribution with a polydispersity index (PD) of 0.31±0.12
and 0.10±0.05, respectively. All other formulations resulted in
preparations with narrow size distributions (PD 0.06±0.02).
All formulations showed a comparable CF to lipid ratio around
0.2, indicating almost the same amount of CF encapsulated into
the different formulations. The variance in CF to lipid ratio for the
1 and 5 mol% DSPE-PEG2000 preparations can be explained by
the greater variance in size compared to the other preparations.
Moreover, for DPPC/DSPC/DSPE-PEG2000 80:10:10 (m/m) a
significant decrease in CF to lipid ratio was observed. This might
be a result of the formation of micelles and membrane discs for
formulations with high DSPE-PEG content [32,33], so this
formulation was excluded from the study. In practice, it is not
necessary to choose a PEG2000-content greater than 5 mol%
which is sufficient to cover the whole surface of the liposomes and
avoid elimination by the RES [5].
3.2. Temperature dependent CF release
The phase transition temperatures of the non P-lyso-PC contain-
ing formulations varied between 41.4 and 44.1 °C (Table 1). The
Fig. 3. Influence of the lipid composition on the time-dependent CF-release rate
of TSL at Tm in FCS. DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m) showed
the fastest content release, followed by the DPPGOG-containing formulation.
The content release properties were also influenced by DSPE-PEG2000. For
5 mol% DSPE-PEG2000 the CF-release rate was increased, whereas for 1 mol%
DSPE-PEG2000 the CF-release rate was decreased compared to DPPC/DSPC
80:20 (m/m). The formulations are given as DPPC/DSPC/DPPGOG/DSPE-
PEG2000/P-lyso-PC (m/m). The calculated rate constants kCF are presented as
10−4 s−1. For every formulation the individual Tm is listed in parenthesis.
Fig. 4. Influence of the lipid composition on the in vitro stability of TSL at
37 °C in FCS. The TSL were diluted with FCS to an appropriate concentration
and incubated at 37 °C using a thermomixer. Samples were collected after
defined time points and the CF leakage was measured fluorometrically. The
formulations are given as DPPC/DSPC/DPPGOG/DSPE-PEG2000/P-lyso-PC
(m/m).
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80:20 (m/m) was not significantly altered by the addition of 1 and
5 mol% DSPE-PEG2000 or 30 mol% DPPGOG. As described
[13,19], the addition of P-lyso-PC to TSL lowers Tm, so DPPC/P-
lyso-PC/DSPE-PEG2000 90:10:4 (m/m) exhibited a phase transition
temperature of 40.9±0.1 °C. The DSC measurements were in
agreement with the temperature dependent content release assay
(Fig. 2) in which all formulations showed a maximum content
release at temperatures approximately one degree below Tm. The
onset of the temperature dependent content release was consistent
with the beginning of the phase transition peak observed with DSC
(data not shown). Further on, the temperature release profile
measured for DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m)
with encapsulated CF was similar in the temperature range from
37 to 41 °C as published for the DOX containing formulation [19].
Interestingly, DPPC/DSPC/DPPGOG 50:20:30 (m/m) behave
differently as the other formulations tested at temperatures above
Tm. In contrast to the non-DPPGOG-containing TSL, where the
amount of CF released at temperatures above Tm was decreased,
the DPPGOG-containing formulation still released more than 60%
CF.
To evaluate the effect of the distinct phospholipids on the
content release rate, the CF-release was measured over time at
Tm for the individual formulation (Fig. 3). DPPC/DSPC/DSPE-
PEG2000 80:20-x:x (x = 0, 1, 5) released less than 20% of CF
during the first 60 s. The content release rate was significantly
increased by incorporating DPPGOG or P-lyso-PC in the
formulation. At the beginning of heating DPPC/DSPC/
DPPGOG 50:20:30 (m/m) and DPPC/P-lyso-PC/DSPE-
PEG2000 90:10:4 (m/m) exhibited a fast release of CF with
N70% within the first 10 s. Afterwards the CF-release of the P-lyso-PC-TSL increased further up to 88.1±5.3% after 60 s
whereas the CF-release of the DPPGOG-TSL remained almost
constant with 75.7±11.6%. The calculated rate constants kCF
are also presented in Fig. 3. However, the rate constant for
DPPC/DSPC/DPPGOG 50:20:30 (m/m) was underestimated
due to the fact, that the CF-release did not follow first order
kinetics in the analyzed time period (0 to 20 s). Compared to
DPPC/DSPC 80:20 (m/m) the DPPGOG containing formula-
tion released CF nine times faster, whereas the incorporation of
P-lyso-PC raised the content release rate by a factor of 22. For
DPPC/DSPC/DSPE-PEG2000 80:20-x:x (m/m), a concentra-
tion dependent effect of DSPE-PEG2000 on the rate constant
was found. Incorporation of 1 mol% PEG2000 decreased the
content release, whereas 5 mol% DSPE-PEG2000 increased the
CF-release at Tm, compared to DPPC/DSPC 80:20 (m/m). The
decrease in membrane permeability for low PEG concentrations
is consistent with the observations by Nikolova et al. [34]. The
maximum permeability of DPPE-PEG2000 liposomes contain-
ing DPPC and PI was previously shown by Nicholas et al. for a
4 mol% PEG2000 formulation [35], a concentration where the
PEG moiety changes from the mushroom to the brush chain
conformation [32].
For optimal TSL-based drug delivery it is important that the
vesicles retain their content when travelling the blood vessels
before reaching the heated tumour. To analyze the effect of the
different lipids on vesicle stability, in vivo conditions were
simulated by performing the experiments in the presence of FCS
at 37 °C. In Table 1 the CF-leakage during 1 h of incubation is
presented. All formulations showed a slow leakage below 4%.
Furthermore, the stability was studied over a time period of 24 h
(Fig. 4). While DPPC/DSPC 80:20 (m/m) was stable up to 12 h
with less then 15% leakage, the 5 mol% PEG2000 formulation
became unstable after 8 h with more than 15% leakage. The
influence of DPPGOG on the TSL stability was less pronounced
Fig. 5. Temperature dependent content release profile of DOX encapsulated in
DPPC/DSPC/DPPGOG 50:20:30 (m/m) TSL. The temperature profile was
measured over 20 min at temperatures from 37 °C to 42 °C. (A) DOX-TSL
measured in HN buffer, pH 7.4. (B) DOX-TSL measured in FCS.
Table 2
DOX release rate constants for DPPC/DSPC/DPPGOG 50:20:30 (m/m) TSL
calculated from the temperature dependent release profile presented in Fig. 5
T (°C) kDOX
HN buffer (10−4 s−1) FCS (10−4 s−1)
38 – 2 (±2)
39 1 (±0) 9 (±2)
40 8 (±3) 61 (±17)
41 64 (±15) 168 (±8)
42 55 (±5) 263 (±102)
43 38 (±15) 236 (±39)
Standard deviations are given in parenthesis.
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CF-leakage was less than 10% during 8 h, comparable with
DPPC/DSPC/DSPE-PEG2000 80:19:1 (m/m). DPPC/P-lyso-
PC/DSPE-PEG2000 90:10:4 (m/m) showed a sustained CF-
leakage with up to 15% during the first 3 h. Thereafter, the
formulation became highly unstable, releasing more than 80%
CF in 8 h.
3.3. Preparation and characterization of DPPGOG-containing
TSL with encapsulated DOX
For the preparation of DPPC/DSPC/DPPGOG 50:20:30
(m/m) with encapsulated DOX (DOX-TSL), a pH gradient driven
loading method was applied [25]. For all loading experiments, a
TSL concentration of 2.5 mM was chosen. The samples were
incubated at 38 °C. The method yielded an almost complete
trapping of DOX inside DPPC/DSPC/DPPGOG 50:20:30 (m/m),as only traces of freeDOXwere detectable during subsequent size
exclusion chromatography. The resultant TSL had a lipid
concentration of 2.1±0.1 mM. The DOX concentration was
0.25±0.02 mM and 0.24±0.01 mM, measured by HPLC and
fluorescence spectroscopy, respectively. Hence, the final drug:
lipid ratio of the preparations was 0.12±0.01 (m/m).
The acidic buffer inside the TSL before the DOX loading
procedure is unfavourable for phospholipids [36]. Storing TSL
with encapsulated 300 mM citrate, pH 4 at 4 °C for weeks
yielded in hydrolysis of the phospholipids and the generation of
lysolipids (data not shown). Hence, we examined the lipid
composition of all DOX-TSL preparations with TLC. The
amount of DPPGOG was 27.8±1.0%. No signs of decomposi-
tion was observed, so the DOX-TSL did not contain detectable
concentrations of lyso-lipids.
3.4. Temperature dependent DOX-release
As mentioned above, drug retention at physiological tempe-
ratures in the presence of serum is crucial regarding a potential
clinical application of TSL. DOX-TSL were incubated for up to
3 h in FCS at 37 °C and the DOX-leakage was followed by
fluorescence spectroscopy. DPPC/DSPC/DPPGOG 50:20:30
(m/m) retained 96.4±1.1% DOX during 1 h of incubation,
which was comparable to the clinically approved non-thermo-
sensitive liposomeCaelyx®, which retained 99.3±1.1%DOX in
this assay. After 3 h the thermosensitive formulation still retained
89.1±4.0% DOX, whereas Caelyx® showed 94.9±2.1% DOX
retention.
Furthermore, the temperature dependent DOX-release pro-
file for the temperature range 37 to 42 °C was measured. First,
the DOX-TSL were incubated in HN buffer (Fig. 5A). The
vesicles remained stable at temperatures up to 39 °C over a time
period of 20 min. DOX-release started at 40 °C and the release
rate increased with increasing temperatures. Incubation at 42 °C
yielded in the fastest DOX-release with 79.9±2.9% in the first
2 min of incubation. For temperatures from 43 to 45 °C the
release profile was not significantly different from the profile
measured at 42 °C (data not shown). Secondly, the temperature
dependent DOX-release profile was measured in FCS (Fig. 5B).
In contrast to the incubation in HN buffer, DOX-release started
already at temperatures ≥38 °C. At 42 °C 97.3±1.4% DOX
was released in the first 2 min of incubation. Again, for
temperatures from 43 to 45 °C the release profile was not
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not shown). To quantify the serum effect, the rate constants
kDOX were calculated (Table 2). In the presence of serum kDOX
was increased 4.8 and 6.2 fold at 42 and 43 °C, respectively. As
expected, the non-thermosensitive liposome Caelyx® did not
show a temperature dependent DOX-release in this assay (data
not shown).
4. Discussion
Although highly clinical relevant for targeted tumour
therapy, there are no data published concerning a successful
clinical application of DOX-TSL in humans to date. The only
in vivo data so far have been accomplished in mice [19] and
dogs [21] and show quite promising results for this treatment
modality. However, the dog study has been hampered by
severe anaphylactic side effects most probably induced by the
lipid formulation used which was based on DSPE-PEG2000
and P-lyso-PC (DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/
m)). Moreover, the pharmacokinetic profile was closer to free
than to liposomal encapsulated drug, indicating an ultra-fast
release due to heating or an insufficient stability of the vesicles
in the bloodstream.
The reason for our study was to test a novel lipid formulation
based on phosphatidyloligoglycerol (DPPGOG) for DOX-TSL
in vitro which might offer an alternative clinical approach to the
ones used to date, especially P-lyso-PC, in the future. Therefore
we compared the influence of DPPGOG, DSPE-PEG2000 and/
or P-lyso-PC on the in vitro stability and drug release properties
of different TSL formulations with encapsulated CF (Table 1).
One prerequisite for clinical application of TSL is a sufficient
high content release rate to achieve therapeutical concentrations in
the heated tumour. The CF-release rate constant kCF at Tm was
notably influenced by the phospholipids used (Fig. 3). Compared
toDPPC/DSPC80:20 (m/m) incorporation of 30mol%DPPGOG
increased kCF 9.4 fold. The effect of DSPE-PEG2000 was
significantly less pronounced, yielding only a 1.3 fold increase in
kCF when incorporated with 5 mol%. Hence, in contrast to DSPE-
PEG2000, DPPGOG is not only able to prolong the in vivo half-
life of TSL [14], it also markedly increases the permeability of
TSL around the phase transition. DPPC/DSPC/DPPGOG
50:20:30 (m/m) and DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4
(m/m) exhibited a comparable fast CF-release with N70% within
the first 10 s. However, DPPC/P-lyso-PC/DSPE-PEG2000
90:10:4 (m/m) showed the fastest CF release rate, with nearly
90% released in the first 60 s of incubation at 40.9 °C. The curve in
Fig. 3 fits well to the observations presented by Mills and
Needham (see Fig. 9 in [37]).
Further on, stability of TSL preparations was also influenced
by distinct phospholipids (Fig. 4). Despite the higher content of
head group modified phospholipid, DPPGOG containing TSL
showed a higher in vitro stability in comparison to the
PEGylated TSL. DPPC/DSPC/DPPGOG 50:20:30 (m/m)
retained CF up to 10 h at 37 °C in serum, whereas PEGylated
TSL became unstable after 6 h. The size of the head group
modification (74 Da versus approximately 2000 Da) is the main
difference between DPPGOG and DSPE-PEG2000 and may beresponsible for this observation. The coupling of the huge
PEG2000 moiety to phosphatidylethanolamine changes the
physical and chemical properties of the phospholipid. The
volume of the polar head group is dramatically increased,
influencing e.g. Tm [16] or the ability to form additional
structures in aqueous solutions like micelles [5,32] or
membrane discs [33]. In DPPGOG, there is no need to reduce
the repulsive steric pressure between the lipid head groups, as
necessary for PEGylated lipids [32]. In contrast to DPPC/
DSPC/DPPGOG 50:20:30 (m/m), the fast-release formulation
DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m) became
highly unstable after 3 h at 37 °C in serum.
According to the presented data of CF-TSL, DPPGOG has
an advantage over DSPE-PEG2000 in TSL formulations.
DPPGOG not only increases the in vivo half-life, it even on
increases the content release rate without the negative effect
observed for DSPE-PEG2000/P-lyso-PC containing TSL on the
stability at 37 °C.
For DPPC/P-Lyso-PC/DSPE-PEG2000 90:10:4 (m/m), Mills
and Needham demonstrated, that DOX was released much
quicker than CF at Tm [15,37]. To examine this for DPPC/DSPC/
DPPGOG 50:20:30 (m/m) and to obtain a clinical relevant
DPPGOG-containing formulation, DOX was successfully encap-
sulated with a drug:lipid ratio of 0.12±0.01 (m/m). The main
difference between CF and DOX release from DPPC/DSPC/
DPPGOG 50:20:30 (m/m) was that DOX was released
completely when incubated 3 min at temperatures ≥42 °C in
FCS (compare Figs. 3 and 5B). The DPPGOG-containing
formulation released 69.7±1.4% DOX and 72.8±1.8% during
18 s at 42 °C and 43 °C, respectively. Nevertheless, the formu-
lation DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m) released
DOX quicker and at 1.5 °C lower temperatures than DPPC/
DSPC/DPPGOG50:20:30 (m/m). At 41.3 °C, a burst release with
100% of DOX released in seconds was observed [15]. However,
the lower permeability at temperatures ≤41 °C of DPPC/DSPC/
DPPGOG 50:20:30 (m/m) had the same positive influence on the
stability at body temperature as observed for the CF-TSL. In
stability experiments, the formulation exhibited only a minor
increase in DOX-leakage compared to the non-thermosensitive
formulation Caelyx® when incubated over 3 h at 37 °C in serum.
Taking into account the two formulations discussed above,
two different strategies for clinical application of drug loaded
TSL are achievable. First, TSL like DPPC/P-lyso-PC/DSPE-
PEG2000 90:10:4 (m/m) release the drug with a burst release at
mild hyperthermic temperatures and damage the tumour
vasculature as a result of high local DOX concentrations
[19,21]. This might lead to a complete shutdown of the tumour
blood flow [38]. Secondly, exploiting the enhanced perme-
ability and retention effect (EPR) liposomes passively accumu-
late in the tumour tissue [39,40] after intravenous application
Thereafter, hyperthermia could be used to release the drug in
therapeutically efficient concentrations. TSL like DPPC/DSPC/
DPPGOG 50:20:30 (m/m) may be more favourable for the
EPR-strategy due to the improved stability at body temperature.
In summary, the choice of the accurate lipid composition for
TSL is important to obtain a formulation that fits all necessary
criteria for clinical application. All tested TSL showed great
2498 M. Hossann et al. / Biochimica et Biophysica Acta 1768 (2007) 2491–2499differences in stability and content release properties. The content
release rate was significantly increased by incorporating DPP-
GOG or P-lyso-PC in TSL formulations. DPPC/DSPC/DPPGOG
50:20:30 (m/m) and DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4
(m/m) exhibited a comparable fast release of CF with N70%
within the first 10 s at Tm. Furthermore, DPPC/DSPC/DPPGOG
50:20:30 (m/m) exhibited an improved stability at 37 °C in serum
compared to the PEGylated TSL. The in vitro properties of
DPPGOG-containing TSL were not significantly changed when
encapsulating DOX instead of CF. In conclusion, DPPGOG has
an advantage over DSPE-PEG2000/P-lyso-PC in TSL formula-
tions, since it not only increases the in vivo half-life, it even on
increases the content release ratewithout the negative effect on the
stability at 37 °C observed for DSPE-PEG2000/P-lyso-PC
containing TSL. This might be a novel option for the design of
TSL in the clinical setting. However, further in vivo evaluation of
this new formulation is warranted.
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